Baiyunshan Pharmaceutical's Unit Amends Production License

MT Newswires Live
10 Apr

Guangzhou Baiyunshan Pharmaceutical's (SHA:600332, HKG:0874) unit, Guangzhou Baiyunshan Mingxing Pharmaceutical, amended its production license after receiving approval from the Guangdong Provincial Medical Products Administration.

The Chinese pharmaceutical company said it will add new production scopes and production lines, as well as confirm its compliance with good manufacturing practices or GMP, in the amended license.

The new production address added to the license is No. 99, Jianxu 3rd Road, Baiyun District, Guangzhou, and the new production workshop is Manufacturing Department 8. The production line, which passed GMP standards, produces lyophilized powder injections for anti-tumor drugs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10